title: Contraceptive potential of the porcine zona pellucida vaccine in the African elephant (Loxodonta africana).
abstract: Immunocontraception has been successful in controlling free-roaming equids; however, what is the potential for the immunocontraceptive control of the African elephant (Loxodonta africana)? The porcine zona pellucida (pZP) glycoproteins share antigenic domains with the African elephant zona pellucida (elZP) glycoproteins, and anti-zona pellucida serum antibodies have been successfully stimulated. To determine the cross-reactivity of the pZP and elZP, immunocytochemistry was evaluated by light and electron microscopy. Specifically, the binding of polyclonal antibodies against total heat-solubilized-porcine zona pellucida to fixed elephant ovary sections was evaluated. The elZP of primary, secondary and tertiary follicles was recognized by the rabbit-anti-pZP serum, but there was no apparent recognition of the primordial follicles. The ability of anti-pZP antibodies to recognize the elZP demonstrates that there is molecular homology between the pZP and elZP glycoproteins. This homology makes the African elephant a candidate for pZP immunocontraception. Three captive elephants were vaccinated with 400 micrograms pZP with a synthetic trehalose dicorynomycolate (S-TDCM) adjuvant. The elephants received 2 boosters of 600 micrograms pZP at 4 wk and 10 m.o. after the primary vaccination. The vaccinated female elephants developed significant (P < 0.05) titers to pZP over prevaccination levels. These levels persisted for 12 to 14 m.o. after the third vaccination. This preliminary evidence shows that the female elephant can develop significant serum antibody levels to pZP. These levels of antibodies are comparable to those required in horses for successful immunocontraception. Thus, porcine zona pellucida immunocontraception might be used to control elephant populations.
authors.affiliation: Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens 30602-7385, USA.
authors.forename: R A
authors.initials: RA
authors.lastname: Fayrer-Hosken
authors.forename: H J
authors.initials: HJ
authors.lastname: Bertschinger
authors.forename: J F
authors.initials: JF
authors.lastname: Kirkpatrick
authors.forename: D
authors.initials: D
authors.lastname: Grobler
authors.forename: N
authors.initials: N
authors.lastname: Lamberski
authors.forename: G
authors.initials: G
authors.lastname: Honneyman
authors.forename: T
authors.initials: T
authors.lastname: Ulrich
mesh_terms: D000818:Animals; D000917:Antibody Formation; D003269:Contraception, Immunologic / Q000379:methods / Q000662:veterinary*; D004527:Egg Proteins / Q000276:immunology*; D004606:Elephants; D005260:Female; D007074:Immunoglobulin G / Q000097:blood; D008562:Membrane Glycoproteins / Q000276:immunology*; D011956:Receptors, Cell Surface; D013019:South Africa; D013552:Swine; D013997:Time Factors; D014612:Vaccines / Q000008:administration & dosage*; D015044:Zona Pellucida / Q000276:immunology*; D000072216:Zona Pellucida Glycoproteins
chemical_list: D004527:Egg Proteins; D007074:Immunoglobulin G; D008562:Membrane Glycoproteins; D011956:Receptors, Cell Surface; D014612:Vaccines; D000072216:Zona Pellucida Glycoproteins